Pharma investors reeled this week from reports that AstraZeneca held merger talks with U.S. rival Bristol Myers Squibb, a move that would break from Big Pharma's decade-long strategy of acquiring smaller companies:
Reports indicate there had been preliminary talks between the U.K. pharma giant and the U.S. company:
A merger could provide AstraZeneca with the necessary scale in the U.S. market, but it may come at the cost of slower growth and integration risks:
Experts see major antitrust and R&D hurdles, making a deal far from certain:
A return to an old playbook?
Following a wave of mega-mergers in the 2000s, the industry shifted toward licensing deals and targeted "bolt-on" acquisitions that allowed larger companies to acquire promising technologies and drug candidates:
Buying U.S. scale in one big move
For AstraZeneca, the clearest benefit could be speed to the key U.S. market:
Scale versus growth
Norstella estimates AstraZeneca could grow at about 5% annually through 2032 based on current consensus forecasts, while a combined company would grow closer to 1%:
